Interstitial Fluid Composition in Patients With Septic Versus Non-septic Shock: an Exploratory Pilot Study
NCT ID: NCT05039151
Last Updated: 2025-12-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
26 participants
OBSERVATIONAL
2021-01-25
2025-07-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
It has been shown in an endotoxemia model that there is a thousandfold higher concentration of ITGB1 in the interstitium compared to the vascular compartment, suggesting a local secretion of this cytokine. The alteration of the extracellular matrix could also play a role in the perpetuation of oedema during septic shock. Considered as an organ in its own right, interstitial tissue is far from playing a passive role between the vascular compartment and the cells. The hypothesis is that interstitial fluid analysis could improve our understanding of the physiopathology of sepsis, in particular on the alteration of the mechanisms of fluid movement regulation, which remains very poorly understood while being closely associated with prognosis in patients with sepsis.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
septic shock
50 patients with a diagnosis of septic shock established within 24 hours of admission with oedemas
interstitial fluid sampling
The sample will be taken via three small catheters (thinner than the catheters used for conventional infusions) under the skin in the abdomen. 1 to 10 ml of interstitial liquid will be collected. A sample will be taken on D1 and D2.
blood sampling
A blood sample (3 x 5 ml EDTA tubes) will be taken simultaneously. A sample will be taken on D1 and D2
control
35 non-septic patients with oedema from another cause
interstitial fluid sampling
The sample will be taken via three small catheters (thinner than the catheters used for conventional infusions) under the skin in the abdomen. 1 to 10 ml of interstitial liquid will be collected. A sample will be taken on D1 and D2.
blood sampling
A blood sample (3 x 5 ml EDTA tubes) will be taken simultaneously. A sample will be taken on D1 and D2
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
interstitial fluid sampling
The sample will be taken via three small catheters (thinner than the catheters used for conventional infusions) under the skin in the abdomen. 1 to 10 ml of interstitial liquid will be collected. A sample will be taken on D1 and D2.
blood sampling
A blood sample (3 x 5 ml EDTA tubes) will be taken simultaneously. A sample will be taken on D1 and D2
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient and/or trusted person (health care proxy) or close relative who has given their oral consent after being informed,
* Age ≥ 18 years old,
* Diagnosis within 24 hours of admission of septic shock as defined by :
* A probable or confirmed infection
* And a SOFA score ≥ 2
* And the need to introduce vasopressors to obtain a MAP ≥ 65 mmHg despite adequate vascular filling
* And an arterial lactate \> 2 mmol/l
* Norepinephrine dose greater than 0.1 μg/kg/min
* Septic shock present for less than 48 hours
\- Absence of sepsis and shock from any cause within 2 months prior to inclusion
Exclusion Criteria
* Acute condition that can mimic sepsis :
* Acute pancreatitis without signs of superinfection
* Metformin Intoxication
* Patient with an unfavourable prognosis within 24 hours
* Patient under legal protection (safeguard of justice, guardianship or tutelage)
* Pregnant or breastfeeding women
* Patient not affiliated to national health insurance
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire Dijon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chu Dijon Bourgogne
Dijon, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LABRUYERE CRBFC-A 2020
Identifier Type: -
Identifier Source: org_study_id